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Abstract
Gastric cancer is the fourth most frequent type of cancer and the second cause of cancer mortality worldwide. The genetic 
alterations described so far for gastric carcinomas include amplifications and mutations of the c-ERBB2, KRAS, MET, TP53, 
and c-MYC genes. Chromosomal instability described for gastric cancer includes gains and losses of whole chromosomes or 
parts of them and these events might lead to oncogene overexpression, showing the need for a better understanding of the 
cytogenetic aspects of this neoplasia. Very few gastric carcinoma cell lines have been isolated. The establishment and char-
acterization of the biological properties of gastric cancer cell lines is a powerful tool to gather information about the evolution of 
this malignancy, and also to test new therapeutic approaches. The present study characterized cytogenetically PG100, the first 
commercially available gastric cancer cell line derived from a Brazilian patient who had a gastric adenocarcinoma, using GTG 
banding and fluorescent in situ hybridization to determine MYC amplification. Twenty metaphases were karyotyped; 19 (95%) of 
them presented chromosome 8 trisomy, where the MYC gene is located, and 17 (85%) presented a deletion in the 17p region, 
where the TP53 is located. These are common findings for gastric carcinomas, validating PG100 as an experimental model 
for this neoplasia. Eighty-six percent of 200 cells analyzed by fluorescent in situ hybridization presented MYC overexpression. 
Less frequent findings, such as 5p deletions and trisomy 16, open new perspectives for the study of this tumor. 
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Gastric cancer (GC) is currently the fourth neoplasia in 
incidence and the second in mortality, and approximately 90% 
of GC are classified as adenocarcinomas (1). The development 
and progression of GC involves alterations in oncogenes and 
tumor suppressor genes, as well as other mechanisms that 
control genomic stability. Alterations described so far include 
amplifications and mutations in the c-ERBB2, KRAS, MET, 
TP53, and c-MYC genes (2,3). The chromosomal instability 
described for GC, represented by gains and losses of whole 
chromosomes or parts of them, shows the need for a better 
understanding of the cytogenetic aspects of this neoplasia. For 
this purpose, the use of cell lines is a powerful tool (3).
Chromosome 8 abnormalities are frequent in many solid 
tumors and hematopoietic proliferations (4,5). The c-MYC 
gene is located in this chromosome at the 8q24.1 band, 
coding a nuclear phosphoprotein whose impact is noticed 
in approximately 15% of the genome (6). This gene is a very 
important regulator of cellular proliferation, differentiation and 
growth, and of the apoptosis process, having, therefore, an 
important function in genome regulation. Deregulation of this 
gene is cited as one of the main events in cancer pathogen-
esis. Recent studies have implicated the MYC oncoprotein 
as a genomic instability mediator since it induces reactive 
oxygen species (ROS), causing aneuploidies (7). Overex-
pression of this gene has been found in approximately 40% 
of gastric malignancies (8).
The establishment and characterization of GC cell lines 
has been used to gather information about the evolution of 
this malignancy, and a large bank of well-characterized cell 
lines could reflect the diversity of tumoral phenotypes, provid-
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ing useful models for the study of this neoplasia. Nevertheless, 
few cell lines originated from gastric tumors are available, and 
most of them are from Asia (4). Our research group character-
ized the first GC cell line in Brazil, called ACP01, and recently 
established and characterized three new GC cell lines (4,9). 
The objective of the present communication is to report 
the cytogenetic characterization of the first commercially 
available Brazilian gastric cancer cell line, PG100, derived 
from the GC of a Brazilian patient and obtained commer-
cially. The line was characterized using GTG banding and 
complemented with evaluation of the MYC gene amplifica-
tion via fluorescent in situ hybridization (FISH).
Material and Methods
PG100 cell line
The PG100 cell line was obtained from Rio de Janeiro 
Cell Bank, Brazil (10). This cell line was established from 
a primary gastric adenocarcinoma of a 29-year-old Brazil-
ian man. PG100 was cultured in 25-cm² culture flasks at 
37°C in HAM-F10 medium plus Dulbecco’s MEM medium 
(Sigma, USA) supplemented with 15% fetal calf serum and 
the antibiotics kanamicin (0.1 mg/mL), ciprofloxacin (0.02 
mg/mL), streptomycin (0.1 mg/mL), and penicillin (99 U/
mL) until they reached confluence, which occurred every 
48 h. For subculture, the cellular monolayer was washed 
using 5 mL Hanks solution (0.4 g KCl, 0.06 g KH2PO4, 
0.04 g Na2HPO4, 0.35 g NaHCO3, 1 g glycose, 8 g NaCl, 
1000 mL H2O) and harvested with trypsin (0.125 g porcine 
trypsin and 0.02 g EDTA diluted in 100 mL Hank’s solu-
tion). Cell split ratio was 1:2 to 1:4 flasks. The PG100 cell 
line grew in a disorganized single layer of cells similar to 
fibroblasts. 
          Conventional cytogenetic analysis 
            Cytogenetic analysis was performed when the cell 
line was in the 8th passage. Briefly, exponentially grow-
ing cells were synchronized and blocked with 0.0016% 
colchicine. Cells were harvested with 0.05% trypsin, 
treated with hypotonic solution (7.5 mM KCl) for 2 h at 
37°C, and fixed with 3:1 methanol/acetic acid. Slides 
were banded using standard trypsin-Giemsa banding 
(GTG-banding). Chromosomes of 100 metaphase 
spreads were counted to determine the modal number 
and 20 metaphases were karyotyped. The description 
of chromosome aberrations was based on the recom-
mendations of the International System for Human 
Cytogenetic Nomenclature (11).
Fluorescence in situ hybridization analysis
FISH was performed on freshly prepared slides 
from cells at the 8th passage fixed in methanol/acetic 
acid. Cells were hybridized with Repeat-Free™ Po-
seidon™ c-MYC (8q24) (KBI-10106, Kreatech Diag-
nostics, Netherlands) according to the manufacturer 
protocol. The nuclei were counterstained with DAPI/
antifade and 200 interphase nuclei were analyzed. 
Positive c-MYC signals appeared as fluorescent red 
spots in the nucleus.
 
Results 
The PG100 cell line was defined as a hyperdiploid 
cell line with a modal number of 49 chromosomes. The 
chromosome number ranged from 33 to 96 in 100 
metaphases analyzed and none of them presented a 
normal karyotype. An alteration was defined as clonal 
when it was present in two or more metaphases with the 
same additional chromosome or structural abnormality 
or three or more metaphases presenting the loss of a 
chromosome as recommended by Ref 11. According 
to these criteria, 24 clonal alterations were found in 
this cell line. Table 1 shows the karyotypes of the 20 
Table 1. Karyotype of 20 PG100 cell line metaphases analyzed.
Cell Karyotype
 1 59,XXY,+5,+8,+9,+10,+11,+13,+14,+15,del(17)(p),+16, 
+19,+21,+22
 2 47,XY,del(2)(p),+8
 3 50,XY,-4,+8,+13,+15,del(17)(p),+19,+20
 4 55,XY,+6,+7,+8,+11,+11,+17,del(17)(p),+18,+21,+22
 5 50,XY,+8,+16,+17,del(17)(p),+18
 6 52,XY,del(4)(p),del(5)(p),+8,+10,+12,+16,del(17)(p),+19, 
+20
 7 50,XY,del(5)(p),+8,+16,+17,del(17)(p),+20,add(22)(q)
 8 55,XY,+8,+11,+15,+16,+17,del(17)(p),+20,+20,+21,+22
 9 55,XY,+5,del(5)(p),+6,+7,+8,del(12)(p),+14,+15,del(17)(p), 
+18,+20,+22
10 43,Y,-X,+8,del(17)(p),-18,-20,-21
11 54,XY,del(3)(p),+4,del(5)(p),+8,+17,del(17)(p),+22, 
add(22)(q)[2],+M,+M,+M
12 50,XY,del(5)(p),+8,+17,del(17)(p)[2],+21,+22
13 54,XY,del(5)(p),+8,+13,+17,del(17)(p),+18,+19,+20,+20,
-21
14 59,XY,+8,+17,del(17)(p),+10dmins
15 57,XY,+8,+11,+12,+17,del(17)(p),+19,+20,+20,+20, 
+2dmins,+ring
16 57,XY,+4,+5,+16,+17,del(17)(p),+18,+18,+19,+21,+22, 
+22,+dmin
17 42,XY,+5,+8,-10,+13,-14,-16,-20,+21,-22
18 45,XY,-1,+3,-7,+8,+10,-14,-18,-20,+21
19 50,XY,+8,del(17)(p),+3dmins
20 57,XY,del(4p),+8,+13,+16,+17,del(17)(p)+7dmins
Composite 
karyotype
43-59,XY,+4,+5,del(5)(p),+6,+7,+8,+10,+11,+12,+13,+14,
+15,+16,+17,del(17)(p), +18,+19,+20,-20,+21,+22
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metaphases analyzed, as well as the composite karyotype 
for this cell line. The most frequent alteration was chro-
mosome 8 trisomy (19 cells/95%) followed by deletion of 
region 17p (17 cells/85%), chromosome 17 trisomy (11 
cells/55%), chromosome 16 trisomy (7 cells/35%), and 
region 5p deletion (6 cells/30%). Double minutes were 
observed in 25% of cells. It is also important to note 
that pair 17 also presented chromatin despiralization in 
the centromeric region, impairing the recognition of this 
chromosome.
c-MYC amplification was evaluated by FISH. Of 200 cells 
analyzed, 149 presented three copies of c-MYC (74.5%), 
but overall c-MYC superexpression (≥3 positive signals) 
was observed in 86%, since 9% (18 cells) presented four 
signals and 2.5% (5 cells) five or more signals. The high-
est number of signals found was eight. A karyotyped cell 
and an interphase nucleus presenting c-MYC trisomy are 
shown in Figure 1.
Figure 1. Cytogenetic analysis of the 
PG100 cell line. A, Karyogram of a 
GTG-banded metaphase. The arrows 
indicate trisomy of chromosomes 5, 6, 
7, 8, 14, 15, 18, 20, and 22; the arrow-
heads indicate deletions in regions 5p, 
12p and 17p. B, Fluorescence in situ 
hybridization analysis of an interphase 
cell. The white arrows show fluorescent 
signals corresponding to three copies 
of MYC.
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Discussion
The cell line presented an extremely aneuploid karyo-
type, a complexity that makes the analysis of these altera-
tions very difficult since cancer chromosomal aberrations 
are complex and hard to interpret, which is a classic difficulty 
in studies involving cytogenetic analysis of neoplasias. Dif-
ferent tumors show a wide range of various chromosomal 
gains and losses, raising questions about the specificity 
and the meaning of many of these changes (12).
Chromosomal instability is considered to have a key 
role in the generation of genetic and phenotypic altera-
tions in cancer cells, being one of the two major genomic 
instability pathways involved in gastric carcinogenesis (13). 
Studies involving conventional cytogenetic techniques have 
revealed frequent amplifications at regions 1q, 2q, 3q, 6q, 
7p, 7q, 8q, 13q, 17q, 20p, and 20q and deletions at regions 
1p, 1q, 2p, 3p, 4q, 5q, 6p, 7q, 9p, 11p, 11q, 12q, 15q, 17p, 
18q, 19p, also including extra X chromosomes and 8, 9, 
or 19 trisomy (8). 
Trisomy 8 was the most frequent abnormality found in 
PG100. Gains of chromosome 8, either trisomies or poly-
somies, are among the most common alterations found in 
malignant gastric tumors (2,3) and in cell lines obtained from 
them, as previously described by our group in a popula-
tion of Northern Brazil (14) and in four GC cell lines (4,9). 
Overamplification of c-MYC was found in 86% of the PG100 
cells analyzed by FISH, confirming previous findings. 
c-MYC codifies a protein that acts as the main regulator 
of many cellular processes, especially cell growth. Deregula-
tion of MYC protein expression can promote DNA replication 
even in the presence of environmental limitations and in 
the absence of growth factors (15). Elevated MYC levels 
create a mutagenic environment in the cells by increasing 
ROS yield and also promoting p53 phosphorylation, an 
indicator of checkpoint activation induced by double-strand 
breaks. When MYC is activated, cells pass through the 
G1/S transition but undergo a p53-dependent G2 arrest, 
which is indicative of accumulation of DNA damage during 
or before the S phase (7). Even though the status of TP53 
in this cell line is unknown, our results suggest that it might 
have lost at least one functional copy (as discussed below). 
Such loss could reduce TP53 cellular function, disrupting 
the G2 arrest caused by MYC-mediated genomic instability, 
and therefore the damages could accumulate, increasing 
the genetic alterations in this cell line.
Another common alteration in the PG100 cell line was 
the deletion of chromosome 17p (85%), where the locus 
of TP53 gene is located, followed by chromosome 17 tri-
somy (55%). Deletion of 17p eliminates the locus of TP53, 
an important factor for carcinogenesis. The present study 
suggests that this gene has lost at least one of its functional 
alleles, which would impair its functions, especially those 
related to cell cycle arrest and DNA repair. Other studies 
also reported extra copies of chromosome 17 with deletion 
of 17p in GC samples (16). 
The PG100 cell line also presented trisomy 16 in 35% 
of the cells analyzed. Although this trisomy is not among 
the most frequent cytogenetic findings in gastric tumors, it 
was previously observed in several GC samples (17), but 
little is known about the importance of this alteration in the 
gastric carcinogenesis process. The 16q region contains 
putative tumor suppressor genes, including CDH1, that 
codes for E-cadherin, a crucial component of the adherence 
junctions between epithelial cells. Mutations in this gene 
are associated with a higher risk for hereditary diffuse-type 
GC and hereditary lobular breast cancer (18).
We also found a deletion in region 5p in 30% of the 
metaphases analyzed. Alterations in this region have 
been reported, but they are not usual. Using the high-
resolution comparative genomic hybridization technique, 
our group previously reported this deletion in 3/24 
diffuse-type GC (19). Many genes involved in important 
metabolic cell functions are located in the 5p region, such 
as DAB2, located at 5p13.1, a putative tumor suppressor 
gene member of the Ras GTPase-activating family. Its 
down-regulation has been reported in several neoplasias, 
including colorectal cancer (20). The loss of 5p in the 
PG100 cell line may lead to a down-expression of DAB2, 
along with other genes, that might play an important role 
in gastric carcinogenesis.
The data presented here suggest that the PG100 cell 
line shares the main genetic alterations found in GC, such 
as trisomy 8 and 17p deletion, which justify the use of this 
cell line as a model to study GC. Our findings also support 
the notion that the MYC gene has a key role in GC due 
to the high frequency of its amplification. Even though our 
results corroborate many cytogenetic findings described 
elsewhere for GC, including the role of MYC in gastric 
carcinogenesis, other less frequent findings such as 5p 
deletion and trisomy 16 open new perspectives for future 
studies concerning this specific neoplasia.
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